Noven acquisition to drive Hisamitsu's US expansion
This article was originally published in Scrip
Executive Summary
The Japanese transdermal specialist Hisamitsu had been saying for several years that it wanted to expand into the US. It has now found a way by paying $428 million for Noven Pharmaceuticals, which has similar interests in the drug delivery area.